AmerisourceBergen 2011 Annual Report Download - page 7

5
A decade
of delivering
innovation
AmerisourceBergen is one of the world’s largest
pharmaceutical services companies, with operations in
the United States, Canada, and the United Kingdom.We
strive to be the preferred partner to healthcare providers
and pharmaceutical manufacturers as we carry out our
mission to improve patient’s lives by delivering innovative
products and services that drive quality and efficiency.
Across our business, our associates achieve success in
the marketplace by adhering to AmerisourceBergen’s
core values: accountability, collaboration, customer
focus, innovation, integrity, and passion. Over the
course of our first decade, we have delivered tremendous
value for our provider and manufacturer customers,
while providing excellent opportunities for our
associates and superior returns to our stockholders.
AmerisourceBergen consists of three operating
segments:AmerisourceBergen Drug Corporation
(ABDC),AmerisourceBergen Specialty Group (ABSG),
and AmerisourceBergen Consulting Services (ABCS).
We believe that we are well-positioned to help our
provider and manufacturer customers continue to take
advantage of growth areas in the market, particularly
around generic pharmaceuticals and specialty
pharmaceuticals and related services.The markets
for generic and specialty products are growing faster
than the overall pharmaceutical market due to launches
of new generic and specialty drugs, as well as the
growing use of increasingly complex therapies, and
the overall increased cost-consciousness in healthcare.
Aging demographics in the U.S. continue to drive
organic growth in the overall pharmaceutical market.
While growth in terms of dollars of sales will be
mitigated somewhat by the large number of branded
pharmaceuticals that are expected to convert to generic
pharmaceuticals over the next few years, we generally
expect the market for pharmaceuticals to continue
to grow.We also expect cost containment initiatives
to drive demand for our services, and for distributors
to continue to become more entrenched than ever in
providing services to manufacturers.A 2011 study of
the role of distributors in the pharmaceutical market
conducted by Booz & Company found that replacing the
distribution model with a model in which manufacturers
distributed their products directly to healthcare providers
would add over $41 billion in costs to the healthcare
system. Our entire industry is focused on continuous
improvement in both the efficiency and safety of the
pharmaceutical supply chain, and enabling healthcare
providers to focus on improving health outcomes
for patients.We believe these efforts will continue
to drive success in the pharmaceutical distribution
industry for the foreseeable future, and will contribute
meaningfully to improving access to pharmaceutical
care and ultimately better health for patients.
As access to healthcare in the U.S. increases as a
result of health reform initiatives, our customers and
suppliers will continue to face close scrutiny regarding
the cost of care and the reimbursement rates for
pharmaceuticals dispensed to patients and for other
healthcare services provided.
AmerisourceBergen is poised
to help providers and
manufacturers meet those
challenges by helping to
ensure that pharmaceutical
products get to market as
quickly and efficiently as
possible, that patients have
access to pharmaceuticals
and that payers and patients
understand the value that
both well-established
therapies and new products
alike provide, and that
We support community and
specialty pharmacies with our
Good Neighbor Pharmacy program,
which provides private label
marketing support, business
coaching and other services.
continued